Indeed, it is well known that the kinase activity of BCR-ABL in CML can activate the downstream MAPK and AKT pathways (7), and RanBP3 has been reported to be the common downstream of the two pathways (26). This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.